We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ekf Diagnostics Holdings Plc | LSE:EKF | London | Ordinary Share | GB0031509804 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 27.30 | 4,728 | 08:12:56 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 26.60 | 27.90 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 52.61M | 2.35M | 0.0052 | 52.50 | 123.87M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 10:03:52 | O | 3,960 | 26.808 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/9/2024 | 06:00 | UK RNS | EKF Diagnostics Holdings PLC Half-year Report |
| 03/9/2024 | 06:00 | UK RNS | EKF Diagnostics Holdings PLC Notice of Results and Investor Presentation |
| 24/7/2024 | 06:00 | UK RNS | EKF Diagnostics Holdings PLC Trading Update |
| 18/7/2024 | 06:00 | UK RNS | EKF Diagnostics Holdings PLC Upgraded Product launch and Contract Wins |
| 15/5/2024 | 20:43 | ALNC |  TRADING UPDATES: Future Metals celebrates state government grant |
| 14/5/2024 | 12:15 | UK RNS | EKF Diagnostics Holdings PLC Result of AGM and Voting Results |
| 14/5/2024 | 09:17 | UK RNS | EKF Diagnostics Holdings PLC AGM Statement & Positive Q1 update.. |
| 14/5/2024 | 06:00 | UK RNS | EKF Diagnostics Holdings PLC AGM Statement & Positive Q1 Trading update |
| 22/4/2024 | 10:53 | UK RNS | EKF Diagnostics Holdings PLC Posting of Annual Report & Notice of AGM |
| 25/3/2024 | 17:15 | UK RNS | EKF Diagnostics Holdings PLC Director/PDMR Shareholding |
Ekf Diagnostics (EKF) Share Charts1 Year Ekf Diagnostics Chart |
|
1 Month Ekf Diagnostics Chart |
Intraday Ekf Diagnostics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/11/2024 | 08:55 | EKF Diagnostics PLC - Cash generative, undervalued and primed for growth! | 153 |
| 23/3/2024 | 09:54 | EKFEREKA | - |
| 23/3/2024 | 09:18 | EKF Diagnostics for income and growth - A healthy, reliable combination! | 3,237 |
| 24/9/2020 | 21:56 | EKF Diagnostics - Growth by acquisition, expertise and special relationships | 1,376 |
| 27/7/2011 | 05:35 | EKF Diagnostics – Growth by acquisition, expert knowledge and special relationsh | 7 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 10:03:53 | 26.81 | 3,960 | 1,061.60 | O |
| 08:51:16 | 26.81 | 120 | 32.17 | O |
| 08:50:05 | 26.60 | 296 | 78.74 | O |
| 08:10:28 | 26.97 | 352 | 94.92 | O |
| 2024-11-04 16:20:44 | 27.20 | 9,492 | 2,581.82 | O |
| Top Posts |
|---|
Posted at 05/11/2024 08:20 by Ekf Diagnostics Daily Update Ekf Diagnostics Holdings Plc is listed in the Med, Dental, Hosp Eq-whsl sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 27.30p.Ekf Diagnostics currently has 453,730,564 shares in issue. The market capitalisation of Ekf Diagnostics is £123,868,444. Ekf Diagnostics has a price to earnings ratio (PE ratio) of 52.50. This morning EKF shares opened at - |
Posted at 04/11/2024 08:55 by wan Staying with Hematology and the supply chain; Managing directors authorised to represent EKF, including EKF's Chief Operating Officer, are speaking at the following meeting -Yin and Yang of the Supply Chain perspectives of supplier and client Friday, November 8, 2024 | 10:00 a.m. - 4:30 p.m. | DECHEMA-Haus, Frankfurt Supply chains have been disrupted for some time now. Whether it's Corona, container ships stuck in the Suez Canal or raw material shortages - it's no longer a given that (intermediate) products arrive at the right place at the right time. How do companies deal with these challenges? How do suppliers and buyers come together under these conditions, and what new paths are companies taking to make their supply chains robust? This is the topic of the 2024 autumn meeting of the Managers' Network, where practitioners from pharmaceuticals, medical technology and diagnostics will report. agenda 10:00 am - Welcome and introduction 10:45 am - Impulse lectures from practice Moderation / discussion: Susanne Simon / Anna-Katharina Heide EKF - We ensure the national blood supply: From the outside in: Process outsourcing and its limits Olga Suckau, COO/ Managing Director EKF Diagnostics EKF - We ensure the national blood supply! In-house production: regain control! Dirk Schulz, Managing Director EKF Diagnostics Balancing act: BIOTYPE as CDMO – Between unclear forecasts, delivery security and demanding product specifications Manja Böhme, CCO Biotype Of challenges and opportunities: Insights from a medium-sized buyer into the supplier landscape Kerstin Korn, COO Biotype Outsourcing in pharmaceutical development: Opportunities and risks of global and local partnerships” Tanja Velmans, Director Portfolio & Strategy Management Analytical Development Novartis 12:20 pm - Discussion |
Posted at 04/11/2024 08:49 by wan I assume that some of the pre-budget indiscriminate selling has depressed EKF's share price. I am hopeful that this effect, pre-budget and general selling, will not be repeated as we close in on the end of 2024 and head into 2025.As we move through the remainder of 2024, in general there are early signs of diminished destocking and stabilised consumable demand in bioprocessing, which is encouraging. Hence there is hope for that to translate into a continued improvement in 2025. With headwinds subsiding, hopefully aiding the increased utilisation of EKF's additional Life Science capacity, it's worth recalling EKF's Outlook statement (including the reference to Hematology) - Outlook Life Sciences has seen good growth in fermentation revenues and β-HB sales have continue to perform well. Within Point of Care, Hematology has delivered a robust performance and we expect to see this improve in H2 based on new shipments to Egypt confirmed and a number of additional wins relating to blood bank centres going live since the period-end. We should see improvements with Diabetes in the second half but as highlighted previously, it is unlikely that these products will reach the revenue levels seen in 2023. It is the nature of a business with a wide variety of products to see mixed performances across this portfolio. The Board remains confident in the outlook for the business overall and with orders already in house for the second half we are very confident that the Point of Care performance in Europe, Middle East and Africa will improve significantly. All of the actions described above are expected to yield further improvements in gross margins, earnings growth and cash generation, and as a result of our efficiency drive we now have a leaner business, with a cost base correctly aligned to a more focussed higher-margin product mix. The Company expects the improvement in performance to continue in H2 2024 and remains confident that full year results will be in-line with market expectations. |
Posted at 21/9/2024 08:19 by wan Looking forward, and coming back to Presentation points worthy of particular mention:EKF's connectivity platform. EKF Link is EKF's in-house developed data and device management system, which is test agnostic and can be used on any platform beyond EKF's analysers. Its adaptability and ease of use make it a valuable connectivity addition to any healthcare setting, including hospitals, laboratories, blood banks, pharmacies, and general practitioners - What also caught my attention (at 36 mins in) is the fact that EKF Link is proving to be so popular that it is also driving enquiries beyond EKF's own point-of-care portfolio, with EKF receiving approaches from companies with 'approved' testing technologies where they haven't got the effective distribution channels that EKF has. The enquiries are not just about utilising EKF Link to provide important connectivity options, with EKF being asked if they would be interested in licensing the other companies products to sell through EKF's firmly established and 'differentiated' distribution channels, in turn providing further opportunities for growth. Subsequently, due to the success and as part of the pivot to a 'multiple' growth opportunities, EKF is looking to expand the connectivity opportunity by putting a commercial team behind EKF Link, driving growth and opening more doors to new opportunities. |
Posted at 21/9/2024 07:06 by wan I don't think there is much doubt that EKF has done the "hard yards" and is now entering a new phase (yes, with some important lessons learned).There are early signs that the second-half will deliver further progress in terms of cash generation and earning growth. The market appears to be responding to this and the fact EKF has delivered significant change in terms of a leaner and more agile business, with a more focussed higher-margin product mix. Recently, I stated that investors need to appreciate the role that EKF's Life Sciences can play, not only in the production of premium OEM products and materials for third-party clinical diagnostic companies (not to mention pharmaceutical and industrial applications), but also in the production of diagnostic products that enable EKF's current diagnostic products, and perhaps under-appreciated, the potential from EKF's future diagnostic tests and devices. This aspect was covered in the Presentation (at around 14mins.53secs in), with EKF investing in utilising enzymes in new product development to deliver new point of care products into EKF's point of care portfolio, which is new and not something they have done before, with a current ongoing product and project to deliver a new state-of-the-art BHB point of care product (current BHB product is for lab-based testing). For those who are prepared to turn the page and look forward, there are several further points that stand out for me, and which I believe are worthy of particular mention. |
Posted at 05/9/2024 12:56 by smithie6 B-HBGLP-1 T1DM as I have posted before anyone posting loads of detailed technical mumbo jumbo, it is surely a complete waste of time for 80-99% of readers who surely have no idea the possible benefit, or not, these things might have to the EKF share price. and the author seems to generally avoid ever indicating what impact on the eps or the share price these things like B-HB might have & that is what most of us are interested in. so, Wan's high tech posts are probably mostly all just water passing by under the bridge, unseen, unnoticed. imo anyway. |
Posted at 15/8/2024 08:35 by wan I am fully cognisant of what occurred in the past (which contain both good and bad elements), so these events are certainly not airbrushed out from my assessments.There is a fact that is perhaps overlooked by statements indicating EKF has gone sideways in terms of growth and potential: In 2019 EKF sold 74m+ Point-of-Care tests. In 2023 EKF sold 95m+ Point-of-care tests (80m in 2022), and are now likely to be knocking on the door of 100m+ tests sold (which could pique outside interest). That type of progress does not come easy and is not currently reflected in the share price, as perhaps indicated by the deep discount to the brokers recent 'upgraded' share price target of 39p. And put another way, a 40% premium bid would still only match the brokers target share price, which remains conservative and may be upgraded. And btw, in that upgrade, the broker commented that EKF is now showing clear evidence that the increased focus on core products is having a beneficial impact on gross margins, earnings growth and cash generation, building on the initial positive signs from Q1. |
Posted at 10/8/2024 08:37 by wan "How will EKFs enzyme work affect those?"First of all it's important to flag that EKF are targeting existing and future products that can deliver healthy margins (hence the rationalisation and investment program). As an example, just one of EKF's diagnostic enzymes, Beta-Hydroxybutyrate Dehydrogenase (B-HB), had sales in 2023 of circa £12m, with an expectation that B-HB sales will deliver improved growth in 2024. Another important factor; is that the investment in precision fermentation technology and larger fermentation vessels at the new facility, has enabled EKF to report that their new fermentation facility is capable of producing 12 months’ of B-HB inventory from just one 3,000L fermentation run (compared to numerous runs previously from smaller vessels), which is a scale EKF has never been able to achieve historically, thereby enabling margin improvement and opening capacity for new customers, and potential to address larger market opportunities (watch this space!). Hopefully, the investment in the fermentation facility will enable EKF to find and deliver the next B-HB enzyme, and indeed more! Beyond enzymes, there are a number of individual initiatives underway that will have a positive effect on margins and profitability. But I am of the opinion that enzymes and 'other' life science products, used across health and industrial applications, will have a material and positive effect upon EKF's business. Overall, the combination of significant investment, and the simplification and rationalisation process of EKF's divisions (expected completion in 2024), should ultimately have a positive and material impact upon profitability and eps going forwards. |
Posted at 24/7/2024 10:10 by wan I don't run entirely with the inevitability of EKF being bought out in the short term, unless future progress and prospects are not properly reflected in the share price. But I note that there is a seller out there that might bring that scenario about (maybe that's a response to the 'pause' in dividends?).However, given the potential enabled by EKF's precision fermentation facility (about which we will find out more detail in due course) high-value contracts will hopefully feature going forwards, and I would not discount key partnerships featuring around certain developments. These type of announcements would obviously cause upgrades accordingly. In short, I want to see both the investment to date, and at least some of the potential realised and accordingly reflected in the share price. We are obviously not there yet, but there is already tangible evidence of very good growth prospects for both divisions, and high-growth potential for the fermentation facility! Interestingly, EKF's precision fermentation facility could ratchet up the growth dynamics of their point-of-care division, if they move forward with producing diagnostic enzymes that enable the manufacture of additional high-margin EKF diagnostic products. In my view, for the patient investor, there is early evidence that indicates there is a combination of good progress and much further potential to be realised. And maybe even the resumption of dividend payments. |
Posted at 10/6/2024 10:06 by wan I am drawn to the recent acquisition of Point-of-Care player Lumira Dx by Roche for $295 million upfront and another cache of up to $55 million, which on its own effectively demonstrates the interest in point-of-care diagnostics.In its last set of recorded revenues, Lumira had $9.2 million in non-COVID sales in the first half of 2023, which equates to around £7m sterling. In 2023, EKF recorded non-Covid sales of £48.7m, with point-of-care recording £32.4m (excluding clinical chemistry and Covid related revenues), which is equivalent to a comparison of around £16m first half revenues compared to Lumira's £7m. (note that EBITDA for the first three months of the year is already showing a c.20% improvement on Q1 2023, and that 2024 will be a year of significant momentum in terms of both EBITDA margins and cash generation). Roche is paying a combined £275m sterling compared to EKF's current market cap of £133m sterling. I appreciate that Roche predominantly bought the technology and not the revenues per se, but it shines at least some light on the value of EKF's globally installed base, and the value of the embedded technology which is further demonstrated by EKF's growing recurring revenues (95 million individual test consumables in 2023). Importantly, EKF's point-of-care technology development is not standing still, which will no doubt be significantly augmented by EKF's new fermentation facility (in contrast to Lumira) e.g. developing and manufacturing enabling consumable diagnostic products (and not just for EKF, but also for medical diagnostics, pharmaceuticals, and industrial applications, facilitating transformative breakthroughs in healthcare and beyond). EKF are doing what Private Equity would do in terms of rationalisation and operational efficiency improvements, which gives pause for thought as to whether AIM is 'ultimately' the right place for listing EKF, or whether those measures and an AIM listing makes EKF an attractive acquisition target (surely it does at the current share price?), and indeed whether Harwood Capitals 29.169% holding will ensure EKF does not succumb to a lowball offer. EKF appears underappreciated (some would say deservedly), despite being debt free, cash generative, undervalued and primed for further growth in 2024. It will therefore be interesting to see whether there is anything beyond a technical pullback in the share price as the quieter summer season approaches, or whether the summer turns out to be an extended hunting season for acquiring UK stocks, with the possibility of EKF being on the menu! Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
Posted at 23/3/2024 09:07 by wan EKF is a global diagnostics and biotechnology company manufacturing and delivering diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care testing and life sciences applications.After rationalisations and investments made over the last two years resulting in a simplified structure of two divisions, Point-of-Care and Life Sciences, EKF is now well placed to deliver sustainable growth and improved returns. In a buy recommended brokers note, Panmure Gordon said: “EKF looks circa 30% undervalued on the basis of the point of care division alone, encouraging progress with customers in the new fermentation facility offers the potential for further upside. Emerging from its transitional period EKF is well positioned for a return to more consistent performance and a strengthening cash position.” Singer Capital Markets broker note: EKF’s FY23 results are in line / slightly ahead of expectations. Growth drivers remain intact in both Point-of-Care and Life Sciences and, with a greater focus on core products, margins should continue to improve from here. This is key to supporting a re-rating and we see considerable value at current levels. With profit forecasts unchanged, we roll forwards our valuation to FY24 and increase our TP to 36p, reiterating our Buy recommendation. (full note available via Research Tree - It's perhaps somewhat underappreciated that EKF has a well-established and comprehensive base of installed Point-of-Care diagnostic users supported by high-quality global distribution channels. In 2023, EKF sold over 12,000 Point-of-Care analysers, resulting in the sale and manufacture of over 95 million individual test consumables. The installed base of diagnostic instruments is currently delivering guaranteed recurring revenues of £35-40m, and is set for further growth in 2024 and beyond (cue Panmure Gordon's point-of-care comment above). In Life Sciences, EKF has invested in a new facility with a full range of fermenters of different capacity, including increased downstream processing, offering contract fermentation services for clinically important enzymes and proteins. EKF Life Sciences is at the forefront of supporting global demand in precision fermentation, enzyme applications and research, providing innovative biotechnology solutions to deliver advancements in healthcare and medicine. Utilising its unique technical expertise, EKF Life Sciences uses precision microbial fermentation and advanced downstream processes to isolate and deliver the highest quality enzymes and biomolecules that have been specially engineered to customer specifications. Customer onboarding has commenced with several fermentation runs completed that will generate revenue in 2024 and will lead to further growth in 2024 as the new customers scale up. With a full range of fermenters of different capacity now online, EKF will look to scale up output throughout 2024 and to add additional customers throughout the current year. EKF are also in active discussions with new fermentation customers for development and scale-up opportunities to come on-line late 2024 and through to 2025. EKF's Outlook Statement: • Investment in our focused core products within Hematology, Diabetes and β-HB will drive further, sustainable growth • Strengthening relationships with key global partners and distribution channels to increase our existing market share in identified core product ranges • 2024 will see the completion of the rationalisation process, resulting in a streamlined core business portfolio, and expansion of fermentation offering • EKF is well placed to deliver growth and improved returns from the investments made over the last two years Presentation - Please conduct your own research when making investment decisions, as the originator, or the threads contributors, could be either wrong or inaccurate. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
